TEVA: 梯瓦制药
今日TEVA汇率已更改-1.04%。当日,交易品种以低点40.80和高点41.59进行交易。
关注梯瓦制药动态。实时报价将帮助您快速应对市场变化。通过在不同的时间周期之间切换,您可以按分钟、小时、天、周和月监控汇率趋势和动态。使用这些信息来预测市场变化并做出明智的交易决策。
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
TEVA新闻
- Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL)
- Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47
- Trump Endorses Netanyahu. What Investors Need To Know About The Israeli Election.
- Israel Elections: AI Stocks, A Defense Winner And Oil Prices In Focus
- J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
- TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament
- TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
- Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy (TEVA)
- Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - Slideshow (NYSE:TEVA) 2026-10-09
- Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
- FDA批准梯瓦公司新的每月一次精神分裂症注射剂
- FDA Approves Teva's New Once-Monthly Schizophrenia Injection
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
- Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval
- 梯瓦制药获 FDA 批准 WELTRUZA 缓释注射混悬液用于治疗成人精神分裂症
- Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
- Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026
- Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette Syndrome
- This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55
- Here's Why You Should Add URGN Stock to Your Portfolio Now
- Teva's Branded Drugs Take Center Stage in Its Growth Strategy
- Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
常见问题解答
TEVA股票今天的价格是多少?
梯瓦制药股票今天的定价为40.85。它在40.80 - 41.59范围内交易,昨天的收盘价为41.28,交易量达到6767。TEVA的实时价格图表显示了这些更新。
梯瓦制药股票是否支付股息?
梯瓦制药目前的价值为40.85。股息政策取决于公司,而投资者也会关注97.77%和USD。实时查看图表以跟踪TEVA走势。
如何购买TEVA股票?
您可以以40.85的当前价格购买梯瓦制药股票。订单通常设置在40.85或41.15附近,而6767和-1.59%显示市场活动。立即关注TEVA的实时图表更新。
如何投资TEVA股票?
投资梯瓦制药需要考虑年度范围20.11 - 42.02和当前价格40.85。许多人在以40.85或41.15下订单之前,会比较3.52%和。实时查看TEVA价格图表,了解每日变化。
梯瓦制药股票的最高价格是多少?
在过去一年中,梯瓦制药的最高价格是42.02。在20.11 - 42.02内,该股波动显著,与相比有助于发现阻力位。使用实时图表跟踪梯瓦制药的绩效。
梯瓦制药股票的最低价格是多少?
梯瓦制药(TEVA)的最低价格为20.11。将其与当前的40.85和20.11 - 42.02进行比较,可以发现潜在的长期切入点。观看TEVA在图表上的实时走势以获取更多详细信息。
TEVA股票是什么时候拆分的?
梯瓦制药历史上曾经历过股票拆分。这些变化在公司行动后的、41.28和97.77%中可见。
- 前一天收盘价
- 41.28
- 开盘价
- 41.51
- 卖价
- 40.85
- 买价
- 41.15
- 最低价
- 40.80
- 最高价
- 41.59
- 交易量
- 6.767 K
- 日变化
- -1.04%
- 月变化
- 3.52%
- 6个月变化
- 16.58%
- 年变化
- 97.77%
- 实际值
- 预测值
- -4.804 M
- 前值
- -8.557 M
- 实际值
- 预测值
- -0.153 M
- 前值
- 1.862 M
- 实际值
- 预测值
- 前值
- 5.420%